Gliosarcoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Astrocytoma, Grade IV
  • +3 more
  • Radiation
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
N
Recruiting
  • Gliosarcoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Active, not recruiting
  • Gliosarcoma
  • Supratentorial Glioblastoma
  • Ipilimumab
  • +3 more
  • San Francisco, California
  • +10 more
2022-04-05
Apr 5, 2022
M
Recruiting
  • Glioblastoma
  • +2 more
  • External Beam Radiation Therapy
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-04-04
Apr 4, 2022
S
Active, not recruiting
  • High Grade Glioma
  • +6 more
  • Birmingham, Alabama
  • +5 more
2022-03-31
Mar 31, 2022
N
Recruiting
  • Glioblastoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +9 more
2022-03-30
Mar 30, 2022
R
Active, not recruiting
  • Glioblastoma
  • Gliosarcoma
  • Laboratory Biomarker Analysis
  • +4 more
  • Boston, Massachusetts
  • +4 more
2022-03-21
Mar 21, 2022
U
Active, not recruiting
  • Glioblastoma Multiforme
  • +2 more
  • Birmingham, Alabama
    University of Alabama at Birmingham
2022-03-15
Mar 15, 2022
F
Completed
  • Glioblastoma
  • Gliosarcoma
  • 3-Dimensional Conformal Radiation Therapy
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-04
Mar 4, 2022
M
Completed
  • Cytomegalovirus Positive
  • +5 more
  • Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
E
Active, not recruiting
  • Glioblastoma
  • Gliosarcoma
  • Dose-Escalated Radiation Therapy
  • +2 more
  • Miami, Florida
  • +2 more
2022-02-16
Feb 16, 2022
L
Suspended
  • Glioblastoma
  • +4 more
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
2022-02-01
Feb 1, 2022
J
Active, not recruiting
  • Giant Cell Glioblastoma
  • +2 more
  • bevacizumab
  • +5 more
  • Los Angeles, California
  • +2 more
2022-02-10
Feb 10, 2022
N
Active, not recruiting
  • Glioblastoma
  • Gliosarcoma
  • Laboratory Biomarker Analysis
  • +4 more
  • Birmingham, Alabama
  • +399 more
2022-02-09
Feb 9, 2022
N
Active, not recruiting
  • Anaplastic Astrocytoma
  • +5 more
  • Birmingham, Alabama
  • +23 more
2022-01-28
Jan 28, 2022
S
Active, not recruiting
  • Glioblastoma
  • +2 more
  • Anti-LAG-3 Monoclonal Antibody BMS 986016
  • +4 more
  • Birmingham, Alabama
  • +10 more
2022-01-28
Jan 28, 2022
U
Recruiting
  • Glioblastoma
  • Gliosarcoma
  • Mycophenolate Mofetil
  • +3 more
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
2022-01-10
Jan 10, 2022
N
Active, not recruiting
  • Glioblastoma
  • Gliosarcoma
  • Laboratory Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +9 more
2022-01-25
Jan 25, 2022
N
Recruiting
  • Glioblastoma
  • +5 more
  • Sonication for opening of blood-brain barrier
  • Chemotherapy, albumin-bound paclitaxel
  • Chicago, Illinois
    Northwestern Memorial Hospital
2022-01-07
Jan 7, 2022
A
Active, not recruiting
  • Glioblastoma
  • Gliosarcoma
  • Phoenix, Arizona
  • +211 more
2021-12-29
Dec 29, 2021
N
Active, not recruiting
  • Giant Cell Glioblastoma
  • +5 more
  • Bevacizumab
  • +4 more
  • Anchorage, Alaska
  • +243 more
2021-12-21
Dec 21, 2021